Vaxart (VXRT) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq set to open higher as CPI, bank earnings take focus; IBM tumbles
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
August 13, 2025 4:05 PM EDTReported positive topline data from Phase 1 clinical trial evaluating Companys second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection Â
Enrolled approximately 5,000 participants in COVID-19 Phase 2b trial prior to stop work order; Follow-up for all participants dosed, including 400-person sentinel cohort continues
Cash, cash equivalents and investments of $26.3 million as of June 30, 2025; Current runway into 2026
Conference call today at 4:30 p.m. ET
Live stockholder fireside chat scheduled on August 20, 2025 at 4:30 p.m. ET to answer frequently... More
